|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.02 / 0.08|
MRCT Amends Agreement Increasing Its Shared Risk in Development of Humanized Antibody
National Institute of Aging Will Continue to Support OX1 Development
Former Head of Discovery Translational Medicine at Wyeth Research and Pfizer Anticipates Intellect's New Class of Improved Antibodies With Better Safety and Efficacy Will be Highly Competitive in Marketplace
Intellectns.com Offers Fresh, User-Friendly Interface for Current and Potential Partners and Investors
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.